Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23848164 | 1.00 | IRAK4 (0.40) | IRAK4EPHA2KDRPDK1DRD4 | |
| SCHEMBL31255481 | 0.77 | EGLN2 (0.43) | — | |
| SCHEMBL23847922 | 0.77 | EGLN2 (0.43) | — | |
| SCHEMBL23847921 | 0.77 | EGLN2 (0.43) | — | |
| SCHEMBL24933231 | 0.74 | PDK1 (0.57) | EPHA2KDRPDK1DRD4 | |
| SCHEMBL30678382 | 0.73 | HRH3 (0.63) | EPHA2KDRPDK1DRD4 | |
| SCHEMBL23835410 | 0.69 | XDH (0.40) | TBK1 | |
| SCHEMBL22588650 | 0.68 | IRAK4 (0.44) | IRAK4PDK1DRD4 | |
| SCHEMBL22588613 | 0.68 | IRAK4 (0.44) | IRAK4PDK1DRD4 | |
| SCHEMBL31255597 | 0.67 | AR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | IRAK4 4042/4885EPHA2 2480/4885KDR 3348/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | IRAK4 4042/4885EPHA2 2480/4885KDR 3348/4885 |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | IRAK4 3909/4885EPHA2 2491/4885KDR 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.